Pharmacoeconomic Evaluation of Axitinib Introduction in Metastatic Renal Cell Carcinoma Treatment Scheme

Pharmacoeconomics: theory and practice
doi 10.30809/phe.3.2014.2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Moscow Pharmaceutical Society

Related search

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Drugs in R and D
Pharmacology
2011English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Axitinib Plus Pembrolizumab Is Effective in Renal Cell Carcinoma

Cancer Discovery
Oncology
2018English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

2012English

Nonablative Hematopoietic Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma

Bone Marrow Transplantation
TransplantationHematology
2002English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Extended Progression-Free Survival of Renal Cell Carcinoma With Axitinib: Case Report

Journal of Urology and Renal Diseases
2018English

Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Targeted Therapies

2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy